8 results
This study is not intended to improve your health, but is necessary for the further development of RO7034067 .The study will be performed in 3 parts, Parts 1, 2 and 3. This document only refers to Part 1/2/3 of the study . Part 1:A single dose will…
To evaluate the effect of baricitinib 4-mg QD and background standard-of-care therapy compared with placebo and background standard-of-care therapy on SLE disease activity.
The purpose of this study is to investigate how safe the new compound BMS-986224 is when it is administered as a single dose to healthy subjects and patients with chronic hart failure. It will also be investigated how quickly and to what extent BMS-…
PrimaryTo evaluate the long-term safety and tolerability of baricitinib in patients with SLE.
A better understanding on the individual response to different albuminuria lowering drugs and a better understanding why these drugs, of which some are developed for another indication, may help to tailor optimal therapy. Therefore in this study…
Primary Objectives: * to establish - which is the best treatment, MTX or baricitinib, to ensure rapid symptom relief of recent onset UA, based on clinical and patient reported outcomes from baseline to 3 months. Secondary Objective: * to establish…
Part A:- Evaluate the safety of increasing doses of a single dose continuous DMT infusion over 90 minutes in healthy smokers - Characterize the pharmacokinetics of a single dose DMT administered continuously over 90 minutes in healthy smokers -…
The primary objective is to test the hypothesis that baricitinib high dose level in combination with topical corticosteroids (TCS) or baricitinib medium dose level in combination with TCS is superior to placebo in combination with TCS in the…